|

Liver Cancer Clinical Trials in San Antonio, TX

19 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple MyelomaPhase 1<1 mi
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)Phase 2<1 mi
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsPhase 1/2<1 mi
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentPhase 1<1 mi
FOG-001 in Locally Advanced or Metastatic Solid TumorsPhase 1/2<1 mi
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver ImpairmentPhase 1<1 mi
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsPhase 1<1 mi
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPhase 1<1 mi
A Study of ZW251 in Participants With Advanced Solid TumorsPhase 1<1 mi
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisPhase 2<1 mi
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaPhase 1/2<1 mi
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic ImpairmentPhase 1<1 mi
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentPhase 1<1 mi
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment—<1 mi
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before SurgeryPhase 2<1 mi
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaPhase 1<1 mi
IDOV-Immune for Advanced Solid TumorsPhase 1<1 mi
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma—<1 mi
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 3<1 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.